Haruo Sugiyama Selected Research

WT1 Proteins

11/2021	Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
11/2018	Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.
8/2018	Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.
1/2017	WT1 peptide cancer vaccine.
12/2015	Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair.
7/2015	Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
8/2014	Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
2/2014	Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
4/2013	HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
12/2012	[WT1-targeting cancer vaccine].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haruo Sugiyama Research Topics

Disease

108	Neoplasms (Cancer) 02/2022 - 05/2002
47	Wilms Tumor (Wilm's Tumor) 01/2022 - 05/2002
32	Leukemia 01/2017 - 08/2002
12	Residual Neoplasm 01/2017 - 03/2003
12	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2017 - 05/2002
11	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 09/2011
11	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2017 - 08/2002
10	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 05/2002
10	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 05/2008
9	Glioma (Gliomas) 01/2022 - 04/2010
9	Hypersensitivity (Allergy) 01/2019 - 09/2009
9	Lung Neoplasms (Lung Cancer) 12/2016 - 07/2002
8	Adenocarcinoma 11/2021 - 08/2003
6	Erythema 06/2012 - 07/2003
6	Breast Neoplasms (Breast Cancer) 05/2010 - 05/2002
5	Disease Progression 01/2022 - 05/2002
5	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 04/2006
4	Multiple Myeloma 01/2022 - 12/2007
4	Graft vs Host Disease (Graft-Versus-Host Disease) 03/2015 - 07/2002
3	Sarcoma (Soft Tissue Sarcoma) 02/2022 - 03/2003
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2015 - 07/2009
3	Stomach Neoplasms (Stomach Cancer) 12/2015 - 05/2009
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2015 - 05/2002
3	Carcinoma (Carcinomatosis) 08/2014 - 07/2011
3	Neoplasm Metastasis (Metastasis) 03/2012 - 05/2006
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2009 - 08/2007
3	Leukopenia 06/2007 - 07/2003
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2003 - 05/2002
2	Ascites 01/2022 - 10/2014
2	Melanoma (Melanoma, Malignant) 08/2019 - 03/2012
2	Carcinogenesis 03/2016 - 05/2009
2	Brain Neoplasms (Brain Tumor) 06/2015 - 07/2009
2	Fibrosarcoma 05/2014 - 04/2006
2	Squamous Cell Carcinoma of Head and Neck 05/2014 - 06/2003
2	Colonic Neoplasms (Colon Cancer) 05/2014 - 05/2009
2	Endometrial Neoplasms (Endometrial Cancer) 08/2010 - 05/2009
2	Lymphoma (Lymphomas) 10/2009 - 01/2008

Drug/Important Bio-Agent (IBA)

78	Peptides (Polypeptides)IBA 02/2022 - 08/2002
45	AntigensIBA 02/2022 - 08/2002
41	WT1 ProteinsIBA 11/2021 - 05/2002
27	VaccinesIBA 02/2022 - 05/2002
23	Protein Subunit VaccinesIBA 02/2022 - 09/2004
20	Messenger RNA (mRNA)IBA 01/2018 - 05/2002
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2003
14	EpitopesIBA 02/2022 - 08/2005
12	Cancer VaccinesIBA 02/2022 - 04/2006
12	HLA-A Antigens (HLA-A)IBA 07/2011 - 08/2002
11	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 08/2002
10	AntibodiesIBA 02/2022 - 05/2002
10	Immunoglobulin G (IgG)IBA 02/2022 - 05/2002
8	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2006 - 07/2002
7	HLA Antigens (Human Leukocyte Antigens)IBA 02/2022 - 03/2004
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2018 - 07/2005
7	DNA (Deoxyribonucleic Acid)IBA 12/2015 - 07/2002
6	Monoclonal AntibodiesIBA 01/2022 - 01/2008
6	Gemcitabine FDA Link 01/2018 - 05/2007
5	HLA-A*24:02 antigenIBA 01/2022 - 12/2012
5	LigandsIBA 01/2021 - 12/2007
5	Small Interfering RNA (siRNA)IBA 12/2016 - 05/2009
5	Protein Isoforms (Isoforms)IBA 12/2015 - 04/2006
5	Tumor Biomarkers (Tumor Markers)IBA 08/2010 - 01/2004
4	Immunoglobulin M (IgM)IBA 02/2022 - 05/2002
4	HLA-A*02:01 antigenIBA 03/2012 - 08/2002
3	InterferonsIBA 10/2017 - 01/2012
3	Monatide (IMS 3015)IBA 03/2012 - 07/2003
2	ProteomeIBA 01/2022 - 12/2017
2	Histocompatibility Antigens Class IIBA 01/2022 - 01/2012
2	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2017
2	CytokinesIBA 05/2020 - 04/2013
2	Cell Wall SkeletonIBA 08/2019 - 07/2004
2	Granzymes (Granzyme)IBA 06/2018 - 04/2013
2	Pharmaceutical PreparationsIBA 01/2018 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2018 - 07/2002
2	Combined VaccinesIBA 01/2018 - 01/2018
2	PicibanilIBA 01/2018 - 10/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2017 - 12/2012
2	Biomarkers (Surrogate Marker)IBA 12/2016 - 01/2008
2	Complementary DNA (cDNA)IBA 12/2016 - 07/2004
2	AutoantibodiesIBA 04/2016 - 05/2014
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2016 - 01/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2015 - 03/2008
2	Temozolomide (Temodar)FDA LinkGeneric 06/2015 - 05/2010
2	HLA-DRB1*04 antigenIBA 03/2015 - 01/2013
2	HLA-DR Antigens (HLA-DR)IBA 01/2015 - 01/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2014 - 08/2010
2	Peptide Elongation Factors (Elongation Factor)IBA 05/2014 - 05/2009
2	Peptide Elongation Factor 2 (EF-2)IBA 05/2014 - 05/2009
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2010 - 01/2008
2	Immunoglobulin IsotypesIBA 05/2007 - 05/2002
2	Indicators and Reagents (Reagents)IBA 05/2006 - 11/2003
2	HLA-A24 AntigenIBA 07/2005 - 08/2002
1	Serum AlbuminIBA 01/2022
1	C-Reactive ProteinIBA 01/2022

Therapy/Procedure

68	Immunotherapy 02/2022 - 05/2002
27	Therapeutics 01/2022 - 04/2006
15	Drug Therapy (Chemotherapy) 01/2022 - 05/2007
4	Hematopoietic Stem Cell Transplantation 01/2017 - 10/2014
3	Stem Cell Transplantation 05/2010 - 03/2003
2	Radiotherapy 06/2015 - 05/2010
2	Intradermal Injections 01/2009 - 07/2004